Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer

BACKGROUND: The antiangiogenic tyrosine kinase inhibitor regorafenib provides a survival benefit in patients with previously treated metastatic colorectal cancer (CRC). Antiangiogenic therapy causes hypoxic stress within tumor cells, which activates autophagy as a survival mechanism. The histone dea...

Descripción completa

Detalles Bibliográficos
Autores principales: Karasic, Thomas B, Brown, Timothy J, Schneider, Charles, Teitelbaum, Ursina R, Reiss, Kim A, Mitchell, Tara C, Massa, Ryan C, O’Hara, Mark H, DiCicco, Lisa, Garcia-Marcano, Luis, Amaravadi, Ravi K, O’Dwyer, Peter J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438902/
https://www.ncbi.nlm.nih.gov/pubmed/35552447
http://dx.doi.org/10.1093/oncolo/oyac078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438902/
https://www.ncbi.nlm.nih.gov/pubmed/35552447
http://dx.doi.org/10.1093/oncolo/oyac078

Ejemplares similares